Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Chronic myeloid leukaemia (CML), drawn from the whole corpus: 18 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
5 medicines on record are linked to one of the types below rather than to Chronic myeloid leukaemia (CML) itself. Grouped by the type that holds them; each list opens that type's own page.
Blast-phase CML: median survival still under a year.
Predicting who can stop TKI safely; second TFR attempts.
Cardiovascular toxicity of nilotinib and ponatinib.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Access to any TKI and to PCR monitoring in LMICs.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 39 changes by month →When this page itself was last checked or edited.
Newly diagnosed Ph+ CML in chronic phase (ASC4FIRST)
ASC4FIRST: higher MMR at 48 weeks than investigator-selected TKI; FDA accelerated approval October 2024.
CML after ≥2 prior TKIs; T315I CML
Chronic myeloid leukaemia (chronic or accelerated phase) with the T315I mutation after prior tyrosine kinase inhibitors
ASCEMBL vs bosutinib in third line.